Dr. Reddy's FTO-11 plant gets two US FDA observations after pre-approval check

Dr. Reddy’s Laboratories said on 8 October 2026 that the US Food and Drug Administration (US FDA) had issued a Form 483 with two observations after a pre-approval inspection of its FTO-11 manufacturing facility at Pydibhimavaram, Andhra Pradesh. The inspection ran from 5 to 7 October 2026, according to the company’s disclosure under Regulation 30 of the SEBI listing rules, which was addressed to the National Stock Exchange of India, BSE, the New York Stock Exchange and NSE IFSC.

The company said it would address the observations within the stipulated timeline. The filing was signed by K Randhir Singh, the company secretary, compliance officer and head of corporate social responsibility. It does not describe the observations, name the product applications linked to the inspection, list the products made at FTO-11 or say how much revenue the site supports.

What a pre-approval inspection tests

A pre-approval inspection checks whether a facility meets good manufacturing practice standards before the US FDA approves pending drug applications, according to Indian Pharma Post, which reported the filing on 12 October. Medical Dialogues reported the disclosure on 9 October and, like the filing, gave no detail on the content of the observations.

Because the inspection was tied to pending applications, its outcome bears directly on the timing of approvals that rely on FTO-11. Dr. Reddy’s has not said which applications those are, how many there are, or whether it expects any change to its launch plans. Nor has it said when it will file its response.

What the market does and does not know

The disclosure gives investors three facts: the type of inspection, its dates and the number of observations. It gives no indication of whether the observations relate to documentation, equipment, processes or quality systems, which is the information readers would need to judge how quickly a response could close them.

The inspection comes after a run of commercial announcements by the company. Dr. Reddy’s website lists recent press releases on an exclusive agreement with Takeda to promote and distribute QDENGA, the launch in India of Nivorz, a nivolumab biosimilar, and an expanded collaboration on lenacapavir. The company’s filing does not connect any of those products to FTO-11.

Dr. Reddy’s is listed in India under the symbol DRREDDY on the NSE and scrip code 500124 on BSE, and in New York under the code RDY.

Our reading

Analysis by The Healthcare Daily.

• Two observations at a pre-approval inspection is a short list, but investors cannot judge severity until Dr. Reddy’s discloses more or the US FDA reports its own view. The filing gives no basis for assuming that approvals tied to FTO-11 will be delayed, or that they will not.
• Because the visit was linked to pending applications, the quality and speed of the company’s response will matter for US launch timing. Analysts should ask on the next earnings call which applications reference FTO-11.
• For Andhra Pradesh’s export manufacturing base, the disclosure is another reminder that US approvals for Indian-made medicines still turn on site-by-site inspection outcomes, and that companies disclose little beyond the count of observations.